Plasma microRNA profiles for bladder cancer detection

Abstract Background Bladder cancer (BC) is a burdensome disease with significant morbidity, mortality, and cost. The development of novel plasma-based biomarkers for BC diagnosis and surveillance could significantly improve clinical outcomes and decrease health expenditures. Plasma miRNAs are promis...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2013-11, Vol.31 (8), p.1701-1708
Main Authors: Adam, Liana, M.D., Ph.D, Wszolek, Matthew F., M.D, Liu, Chang-Gong, Ph.D, Jing, Wang, Ph.D, Diao, Lixia, Ph.D, Zien, Alexander, Ph.D, Zhang, Jitao D, Jackson, David, Ph.D, Dinney, Colin P.N., M.D
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Diagnosis, Differential
Feasibility Studies
Female
Gene Expression Regulation, Neoplastic
Humans
Logistic Models
Male
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
Neoplasm Invasiveness
Oligonucleotide Array Sequence Analysis - methods
Prognosis
Reproducibility of Results
Reverse Transcriptase Polymerase Chain Reaction - methods
Sensitivity and Specificity
Transcriptome
Urinary Bladder Neoplasms - blood
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - genetics
Urology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Bladder cancer (BC) is a burdensome disease with significant morbidity, mortality, and cost. The development of novel plasma-based biomarkers for BC diagnosis and surveillance could significantly improve clinical outcomes and decrease health expenditures. Plasma miRNAs are promising biomarkers that have yet to be rigorously investigated in BC. Objective To determine the feasibility and efficacy of detecting BC with plasma miRNA signatures. Materials and methods Plasma miRNA was isolated from 20 patients with bladder cancer and 18 noncancerous controls. Samples were analyzed with a miRNA array containing duplicate probes for each miRNA in the Sanger database. Logistic regression modeling was used to optimize diagnostic miRNA signatures to distinguish between muscle invasive BC (MIBC), non-muscle-invasive BC (NMIBC) and noncancerous controls. Results Seventy-nine differentially expressed plasma miRNAs (local false discovery rate [FDR]
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2012.06.010